Montelukast Treatment Guidelines

Introduction to Montelukast Therapy

The American Academy of Allergy, Asthma, and Immunology recommends that montelukast should be continued as long as the underlying condition requires treatment, meaning daily, ongoing therapy throughout the allergen exposure period for allergic rhinitis, or indefinitely for persistent asthma as a controller medication 1, 2

The American Academy of Pediatrics recommends that a 12-year-old should receive the 10 mg tablet, as the 5 mg chewable formulation is only appropriate for children 6-14 years, and most 12-year-olds fall into the adolescent dosing category 3

For seasonal allergic rhinitis, the American Academy of Allergy, Asthma, and Immunology recommends initiating montelukast before the anticipated pollen season begins and continuing throughout the entire allergen exposure period 4
For perennial allergic rhinitis, the American Academy of Allergy, Asthma, and Immunology recommends continuing daily therapy year-round due to unavoidable, ongoing allergen exposure 4
For persistent asthma, the American Academy of Allergy, Asthma, and Immunology recommends using montelukast as a long-term daily controller medication indefinitely, as long as asthma control requires it 1

The American College of Physicians recommends that intranasal corticosteroids are significantly more effective than montelukast for allergic rhinitis and should be the first-line treatment 6, 7, 8
The American Thoracic Society recommends that inhaled corticosteroids are more effective than leukotriene receptor antagonists and remain the preferred long-term control medication for asthma 1

The FDA recommends that before prescribing montelukast, explicitly counsel parents about serious neuropsychiatric risks including suicidal thoughts, depression, anxiety, sleep disturbances, and behavioral changes 3
The FDA recommends monitoring for unusual behavioral or mood changes, particularly in the first weeks of therapy 3

The American Academy of Allergy, Asthma, and Immunology recommends never using montelukast for acute asthma exacerbations or as rescue therapy, and ensuring a short-acting beta-agonist is available for acute symptoms 3
The American Academy of Allergy, Asthma, and Immunology recommends not discontinuing montelukast when symptoms improve, as it provides continuous control and must be taken daily 4
The American College of Physicians recommends recognizing that montelukast is less effective than inhaled/intranasal corticosteroids, and it should not be the first choice unless corticosteroids are contraindicated or refused 1, 6, 7